Monday 9 November 2026
Export RMTI’s income statement to Excel — free account
Rockwell Medical, Inc.
RMTIHealthcare Drug Manufacturers Specialty & Generic
Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- +32.0%
- Free cash flow
- −12.9%
- Total debt
- −1.73%
Quarter to June 2026, against a year earlier
7.73
0.13
+1.71%
Follow RMTI
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (15.53%) | (16.04%) | (15.28%) | (17.14%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 3 | 3 | |
| (9.32%) | (9.70%) | (9.13%) | (9.90%) | ||
ROIC |
(14.58%) | (14.27%) | (13.89%) | (13.38%) | |
Return on Tangible Assets |
(17.06%) | (17.21%) | (16.00%) | (17.24%) | |
Average Days of Receivables |
43.69 | 47.59 | 42.91 | 40.22 | |
Free Cash Flow per Share |
0.43 | 0.49 | (0.33) | (0.81) | |
Free Cash Flow |
1.72 | 1.93 | (1.20) | (2.94) | |
Capital Expenditures |
(1.18) | (0.73) | (0.54) | (0.85) | |
| Other line items | |||||
Cash ROIC |
2.49% | 2.81% | (1.69%) | (4.20%) | |
Accounts Receivable Turnover |
8.47 | 7.32 | 8.43 | 8.78 | |
Accounts Payable Turnover |
24.40 | 20.90 | 23.65 | 31.06 | |
Inventory Turnover |
16.37 | 13.86 | 12.51 | 13.02 | |
Average Days of Payables |
20.32 | 22.41 | 12.68 | 8.67 | |
Days of Inventory on Hand |
18.01 | 19.87 | 21.71 | 22.56 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.33% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
24.17% | 24.17% | 23.66% | 21.51% | |
Share Based Compensation of Revenue |
2.70% | 2.73% | 2.62% | 2.30% | |
Interest Coverage |
(3.99) | (4.26) | (4.17) | (4.27) | |
Operating CF/Net income |
(0.57) | (0.49) | 0.12 | 0.37 | |
Depreciation/Fixed assets |
0.53 | 0.58 | 0.55 | 0.51 | |
Capex/Depreciation |
(0.48) | (0.29) | (0.21) | (0.33) | |
Revenue per Share |
17.53 | 17.17 | 19.25 | 20.98 | |
Operating CF per Share |
0.73 | 0.68 | (0.18) | (0.58) | |
Capex per Share |
(0.30) | (0.18) | (0.15) | (0.24) | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 26 Oct 2026